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patients and those on immuno-suppression. There are four known
genotypes of HEV. The most recent candidate vaccines have been
two recombinant HEV vaccines. The ﬁrst of these vaccines was
based on a 56-kDa baculovirus-expressed ORF2 protein produced
in Spodoptera frugiperda cells, developed at the National Institutes
of Health, later licensed to GlaxoSmithKline. A phase II clinical
trial was conducted in 1,794 young male military recruits in Nepal
who received three doses 20g of the alum-adjuvanted vaccine
or placebo. Vaccinees were followed up to 2.2 years. The vaccine
showed a 95% efﬁcacy after the third dose. This vaccine study was
limited by the fact that it was tested on almost exclusively young
males, it did not measure the HEV infection rate and that antibody
titers declined by the end of the study. The second vaccine was
developed by researchers at Xiamen University in China, using a
new recombinant HEV protein expressed in Escherichia coli. This
vaccine, HEV 239 (Hecolin), was tested in a randomized, controlled
trial involving 112,604 healthy participants aged between 16-65
years in Jiangsu Province, where HEV genotypes 3 and 4 are more
prevalent. In those who received all three doses, 87% maintained
antibodies and remained protected against HEV for up to 4.5 years.
Its efﬁcacy against HEV genotypes 1 and 2, in pregnant women and
those younger than 16 years and older than 65 years are yet to
be assessed. The vaccine is licensed for use in China. Though not
yet prequaliﬁed by the WHO, the WHO is ready to assist national
health authorities and regulators in a rapid assessment of this vac-
cine. Today, the real challengewill be to get anHEVvaccine to those
who need it the most, at an affordable price.
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Background: Pentavalent combination vaccines perform a key
role in increasing vaccine coverage rate; and provide an efﬁcient
and reliable method of implementing WHO recommendations for
controlling diphtheria, tetanus, pertussis, hepatitis B andHib infec-
tions on a worldwide basis.
Methods & Materials: Study design: A phase III, multi-center,
randomized, single blinded study of a fully liquid pentavalent
DTwP-HepB-Hib investigational vaccine (Shan5TM) was conducted
across India in healthy toddlers and infants. Cohort 1 consisted of
15 toddlers aged 15-18months, administeredwith a single booster
dose; Cohort 2 consisted of 1085 infants aged 6-8 weeks, adminis-
tered 3 doses at 6-8, 10-12 and 14-16 weeks of age.
Objectives: Subjects in Cohort 1 were evaluated for safety and
immunogenicity. Immunogenicity and safety were evaluated in
Cohort 2 subjects vaccinated with a three-dose primary immu-
nization of either the investigational vaccine or a locally licensed
comparator vaccine (PentavacTM SD). Immune consistency anal-
ysis among three lots of the investigational vaccine, and immune
non-inferiorityanalysisofpooled (three lots)dataof investigational
vaccine versus comparator vaccine were also evaluated in cohort
2.
Results: The vaccines demonstrated comparable safety and
immune responses in cohort 1. In cohort 2, immune non-inferiority
against the comparator vaccine (primary endpoint) was demon-
strated for all ﬁve antigens and safety results (secondary endpoint)
were comparable between vaccine groups. Equivalent immune
consistency among three lots was observed for all antigens except
whole cell pertussis antigens, where a marginal variation was
observed. The variation was linked to the low power of the test
and concluded to be clinically insigniﬁcant.
Conclusion: The investigational, fully-liquid,whole-cell pertus-
sis (wP) containing pentavalent vaccine has a good safety proﬁle
and immunologically non-inferior to the licensed comparator vac-
cine. This study was the basis for licensure in India and also WHO-
prequaliﬁcation for international use.
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Background: Studies on county-level hot spots of sexually
transmitted infections (STIs) in the entire U.S. and their associ-
ation with socio-economic factors are lacking. In this study, we
used a combination of hot spot analysis (HSA) and spatial regres-
sion to examine the county-level correlates of the most commonly
reported curable sexually transmitted infections (STIs) in the U.S.
Methods & Materials: We obtained reported county-level total
case rates of chlamydia, gonorrhea, and primary and secondary
(P&S) syphilis in all counties in the 48 contiguous states using
the National Notiﬁable Disease Surveillance System (NNDDS).
We computed temporally-smoothed rates using 2008–2012 data.
Covariateswereobtained fromcounty-levelmultiyear (2008-2012)
American Community Surveys (ACS) from the US census. We con-
ducted HSA (applying the false discovery rate (FDR) correction) to
identify hot spot counties for all three STIs. Hot spots were deﬁned
as counties or clusters of countieswith rates above the globalmean
(p<0.05). We used logistic spatial regression with the spatial error
model (SEM) to determine the association between hot spots and
the covariates and variance inﬂation factor (VIF <10) analysis to
reduce the effect of multicollinearity on the coefﬁcients.
Results: HSA indicated that ≥ 80% of hot spots for each STI were
in the South. Spatial regression results indicated that, compared to
White non-Hispanics, a 1% increase in the percentage Black non-
Hispanic was associated with a 3.3% (p<0.01; chlamydia), 3.8%
(p<0.01; gonorrhea) and 2.5% (p<0.01; P&S syphilis) increase in
the odds of being a hot spot county (Table 1). Compared to the other
regions (West, Midwest andNortheast), counties in the Southwere
